Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization

Saudi Journal of Ophthalmology

Volumn 29, Issue 4, 2015, Pages 287-291

  Sadiq, Mohammad Ali ^a   Hanout, Mostafa ^a   Sarwar, Salman ^a   Hassan, Muhammad ^a   Do, Diana V ^a   Nguyen, Quan Dong ^a   Sepah, Yasir Jamal ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Age related macular degeneration; Diabetic retinopathy; PDGF; Platelet derived growth factor; Retinal vascular disease

Indexed keywords

AGENTS ACTING ON THE EYE; PEGPLERANIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR INHIBITOR; PROTEIN INHIBITOR; RANIBIZUMAB; UNCLASSIFIED DRUG;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; COMPARATIVE STUDY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION STUDY; HUMAN; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA NEOVASCULARIZATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84952873484     PISSN: 13194534     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjopt.2015.05.005     Document Type: Review

References (33)

1. Demoulin JB, Montano-Almendras CP. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res 2012;2(1):44-56 PubMed PMID: 22432087. Pubmed Central PMCID: PMC3301440. Epub 2012/03/21. Eng.
2. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22(10):1276-312 PubMed PMID: 18483217. Pubmed Central PMCID:PMC2732412. Epub 2008/05/17. Eng.
3. Edqvist PH, Niklasson M, Vidal-Sanz M, Hallbook F, Forsberg-Nilsson K. Platelet-derived growth factor over-expression in retinal progenitors results in abnormal retinal vessel formation. PloS One 2012;7(8):e42488 PubMed PMID: 22880002. Pubmed Central PMCID: PMC3411765. Epub 2012/08/11. Eng.
4. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79(4):1283-316 PubMed PMID: 10508235. Epub 1999/10/03. Eng.
5. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006;81(9):1241-57 PubMed PMID: 16970222. Epub 2006/09/15. Eng.
6. Fruttiger M, Calver AR, Richardson WD. Platelet-derived growth factor is constitutively secreted from neuronal cell bodies but not from axons. Curr Biol: CB 2000;10(20):1283-6 PubMed PMID:11069109. Epub 2000/11/09. Eng.
7. Reneker LW, Overbeek PA. Lens-specific expression of PDGF-A in transgenic mice results in retinal astrocytic hamartomas. Invest Ophth Vis Sci 1996;37(12):2455-66 PubMed PMID: 8933762. Epub 1996/11/ 01. Eng.
8. Tang Z, Arjunan P, Lee C, Li Y, Kumar A, Hou X, et al. Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. J Exp Med 2010;207(4):867-80 PubMed PMID: 20231377. Pubmed Central PMCID: 2856029.
9. Wang Y, Abu-Asab MS, Yu CR, Tang Z, Shen D, Tuo J, et al. Plateletderived growth factor (PDGF)-C inhibits neuroretinal apoptosis in a murine model of focal retinal degeneration. Lab Invest; A J Tech Method Pathol 2014;94(6):674-82 PubMed PMID: 24709779. Pubmed Central PMCID: 4039574.
10. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (New York, NY) 1997;277(5323):242-5 PubMed PMID: 9211853. Epub 1997/07/11. Eng.
11. Mudhar HS, Pollock RA, Wang C, Stiles CD, Richardson WD. PDGF and its receptors in the developing rodent retina and optic nerve. Development (Cambridge, England) 1993;118(2):539-52 PubMed PMID: 8223278. Epub 1993/06/01. Eng.
12. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford, England) 2008;47 Suppl 5:v2-4 PubMed PMID: 18784131. Epub 2008/09/17. Eng.
13. Grimminger F, Schermuly RT. PDGF receptor and its antagonists: role in treatment of PAH. Adv Exp Med Biol 2010;661:435-46 PubMed PMID: 20204747. Epub 2010/03/06. Eng.
14. Hosaka K, Yang Y, Seki T, Nakamura M, Andersson P, Rouhi P, et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nature Commun 2013;4:2129.
15. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Can Res 2006;66(17):8715-21.
16. Crino L, Metro G. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev: An Off J Eur Respir Soc 2014;23(131):79-91 PubMed PMID: 24591665. Epub 2014/03/05. Eng.
17. Michaelson I. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948;68:137-80.
18. Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, et al. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993;142(4):1119-30.
19. Inaba T, Ishibashi S, Gotoda T, Kawamura M, Morino N, Nojima Y, et al. Enhanced expression of platelet-derived growth factor-beta receptor by high glucose involvement of platelet-derived growth factor in diabetic angiopathy. Diabetes 1996;45(4):507-12. PubMed PMID: 8603774. Epub 1996/04/01. Eng.
20. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, Yamada H, et al. Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol 2000;157(3):995-1005 PubMed PMID: 10980138. Pubmed Central PMCID: PMC1885694. Epub 2000/09/12. Eng.
21. Koyama N, Watanabe S, Tezuka M, Morisaki N, Saito Y, Yoshida S. Migratory and proliferative effect of platelet-derived growth factor in rabbit retinal endothelial cells: evidence of an autocrine pathway of platelet-derived growth factor. J Cell Physiol 1994;158(1):1-6 PubMed PMID: 7505273. Epub 1994/01/01. Eng.
22. Freyberger H, Brocker M, Yakut H, Hammer J, Effert R, Schifferdecker E, et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabet: Off J, German Soc Endocrinolo and German Diabetes Assoc 2000;108(2):106-9 [PubMed PMID: 10826517. Epub 2000/05/29. Eng].
23. Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I, et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Visual Sci 1994;35(10):3649-63 PubMed PMID: 8088954. Epub 1994/ 09/01. Eng.
24. Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog JK, Baumann M, et al. Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis 2013 PubMed PMID: 24154861. Epub 2013/10/25. Eng].
25. Ophthotech C. A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration. US National Institutes of Health. 2007 2013 December 12 .
26. Jordi Mones M. Barcelona, Spain. Inhibiting VEGF and PDGF to Treat AMD REVIEW of Ophthalmology2011 http://www. revophth.com/content/d/retinal_insider/c/29979/.
27. Ophthotech C. A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration. US National Institutes of Health. 2010 2013 December 12 .
28. Dugel, PU. Anti-PDGF combination therapy in neovascular agerelated macular degeneration: results of a phase 2b study. RETINA TODAY. March, 2013 .
29. A Phase 3 Safety and Efficacy Study of Fovista ™ (E10030) Intravitreous Administration in Combination With Lucentis ® Compared to Lucentis ® Monotherapy 2013 .
30. A Phase 3 Safety and Efficacy Study of Fovista ™ (E10030) Intravitreous Administration in Combination With Either Avastin ® or Eylea ® Compared to Avastin ® or Eylea ® Monotherapy; 2013.
31. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119(7):1388-98 PubMed PMID: 22555112. Pubmed Central PMCID: PMC3389193. Epub 2012/05/05. eng.
32. Dugel PU. Anti-PDGF combination therapy in neovascular agerelated macular degeneration: results of a phase 2b study 2013; (March).
33. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytok Growth Factor Rev 2004;15(4):215-28 PubMed PMID: 15207813. Epub 2004/06/23. Eng.